Research programme: glutamate carboxypeptidase II inhibitors - Eisai

Drug Profile

Research programme: glutamate carboxypeptidase II inhibitors - Eisai

Latest Information Update: 28 Sep 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johns Hopkins Brain Science Institute; MGI GP
  • Developer Eisai Co Ltd; Johns Hopkins Brain Science Institute
  • Class Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Glutamate carboxypeptidase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Eye disorders; Pain
  • Research Neurological disorders

Most Recent Events

  • 25 Sep 2012 Santen Pharmaceuticals enters option agreement to license opthalmological compounds from Eisai
  • 12 Mar 2010 Early research in Neurological disorders in USA (unspecified route)
  • 29 Jan 2008 Eisai acquires MGI PHARMA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top